疼痛管理薬の世界市場2019–2027:薬剤クラス別(NSAIDS、麻酔薬、抗けいれん薬、抗片頭痛薬、抗うつ薬、オピオイド、非麻薬性鎮痛薬)、疾患別

◆英語タイトル:Pain Management Drugs Market by Drug Class, (NSAIDS, Anesthetics, Anticonvulsant, Anti-Migraine Drug, Antidepressant Drugs, Opioids, and Non-Narcotic Analgesics) and Indication (Arthritic Pain, Neuropathic Pain, Cancer Pain, Chronic Pain, Post-Operative Pain, Migraine, and Fibromyalgia): Global Opportunity Analysis and Industry Forecast, 2019–2027
◆商品コード:AMR20OC047
◆発行会社(リサーチ会社):Allied Market Research
◆発行日:2020年8月
◆ページ数:216
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD6,168 ⇒換算¥666,144見積依頼/購入/質問フォーム
5 UserUSD6,929 ⇒換算¥748,332見積依頼/購入/質問フォーム
Enterprise UserUSD9,663 ⇒換算¥1,043,604見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はAllied Market Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Allied Market Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本調査レポートでは、疼痛管理薬の世界市場を広く調査・分析し、イントロダクション、エグゼクティブサマリー、市場動向、薬剤クラス別分析(NSAIDS、麻酔薬、抗けいれん薬、抗片頭痛薬、抗うつ薬、オピオイド、非麻薬性鎮痛薬)、疾患別分析(関節炎、神経因性疼痛、がん性疼痛、片頭痛、術後痛み)、地域別分析情報、競争状況、企業情報など、以下の構成でまとめております。
・イントロダクション
・エグゼクティブサマリー
・市場動向
・疼痛管理薬の世界市場規模:薬剤クラス別(NSAIDS、麻酔薬、抗けいれん薬、抗片頭痛薬、抗うつ薬、オピオイド、非麻薬性鎮痛薬)
・疼痛管理薬の世界市場規模:疾患別(関節炎、神経因性疼痛、がん性疼痛、片頭痛、術後痛み)
・疼痛管理薬の世界市場規模:地域別
・競争状況
・企業情報
【レポートの概要】

The global pain management drugs market was valued at $65,963.1 million in 2019, and is estimated to reach $85,549.3 million by 2027, registering a CAGR of 3.9% from 2020 to 2027. Pain is a distressing sensory and emotional sensation, which is caused by tissue injury or disease. Moreover, different disorders may cause discomfort, such as multiple sclerosis, osteoarthritis, stomach ulcer, chronic arthritis, fibromyalgia, diabetic neuropathy, and cancer. The length of the pain would range from acute pain for short term to chronic pain for long term. Acute pain is a sudden onset of pain when chronic pain is caused by aged bone & joint conditions, nerve damage, or injury. Pain management involves reducing or treating pain by using a given range of medications. There are several medicines available, which provide pain relief through a variety of physiological mechanisms such as targeting nociceptors.

Rise in geriatric population is the major factor that drives growth of the global pain management market, as aged people are more prone to suffer from joint pain and other chronic conditions. For instance, prevalence of chronic diseases such as cancer is on the rise. As per the National Cancer Institute, almost 20 to 50% of people with cancer suffer from pain. Around 80% of patients with advanced stage cancer suffer from moderate to severe pain. Moreover, surge in prevalence of chronic diseases, such as cancer, diabetic neuropathy, and osteoarthritis propels the market growth. Furthermore, rise in number of surgical procedures and rise in healthcare expenditure are expected to fuel growth of the market. However, drug exploitation, patent expiration of prescription pain medication drugs, and availability of substitutes such as pain relief devices restrain the market growth.

The global pain management drugs market is segmented on the basis of drug class, indication, and region On the basis of drug class, the market is categorized into nonsteroidal anti-inflammatory drugs (NSAIDs), anesthetics, anticonvulsants, antimigraine agents, antidepressants, opioids, and nonnarcotic analgesics. Opioids are further classified into tramadol, hydrocodone, oxycodone, and others (fentanyl, morphine, meperidine, codeine, and methadone). On the basis of indication, the market is divided into arthritic pain, neuropathic pain, cancer pain, chronic back pain, postoperative pain, migraine, and fibromyalgia. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS
 The study provides an in-depth analysis of the global pain management drug market along with the current trends and future estimations to elucidate the imminent investment pockets.
 A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
 The market forecast is studied from 2020 to 2027
 Comprehensive quantitative analysis of the industry from 2019 to 2027 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
 Extensive analysis of the key segments of the industry helps to understand the application and products of pain management used across the globe.
 Key market players and their strategies have been analysed to understand the competitive outlook of the market.

KEY MARKET SEGMENTS
By Drug Class
• NSAIDs
• Anesthetics
• Anticonvulsants
• Anti-migraine Agents
• Antidepressants
• Opioids
o Tramadol
o Hydrocodone
o Oxycodone
o Others
• Nonnarcotic Analgesics

By Indication
• Arthritic Pain
• Neuropathic Pain
• Cancer Pain
• Chronic Back Pain
• Postoperative Pain
• Migraine
• Fibromyalgia

By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
• Asia-Pacific
o Japan
o China
o Australia
o India
o South Korea
o Taiwan
o Rest of Asia-Pacific
• LAMEA
o Brazil
o Saudi Arabia
o South Africa
o Rest of LAMEA

KEY MARKET PLAYERS
• Abbott Laboratories
• Eli Lilly & Company
• Endo Health Solutions, Inc.,
• GlaxoSmithKline Plc.
• Johnson & Johnson
• Merck & Co. Inc.
• Mylan NV.
• Novartis AG
• Pfizer, Inc.
• Purdue Pharma L.P.

OTHER PROMINENT MARKET PLAYERS
• Allergen Inc.
• Bayer AG
• Bristol-Myers Squibb
• Boehringer Ingelheim
• Sorrento Therapeutics
• Valeant Pharmaceuticals International Inc.
• WEX Pharmaceuticals
• Zynerba Pharmaceuticals.

【レポートの目次】

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
1.4.4.Primary research

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key Findings

3.2.1.Top investment pockets
3.2.2.Top winning strategies

3.3.Top player positioning
3.4.Porter’s five force analysis
3.5.Government Regulations
3.6.Market dynamics

3.6.1.Drivers

3.6.1.1.Rise in incidences of chronic diseases
3.6.1.2.Favorable regulatory scenario
3.6.1.3.Increase in geriatric population

3.6.2.Restraints

3.6.2.1.Availability of alternative therapies
3.6.2.2.Drug Exploitation
3.6.2.3.Patent expiration of prescription drugs

3.6.3.Opportunities

3.6.3.1.Advancements in drug development
3.6.3.2.Untapped markets in developing economies

3.7.COVID-19 Impact Analysis for Pain Management Drugs

CHAPTER 4:GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS

4.1.Overview

4.1.1.Market size and forecast

4.2.NSAIDS

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country

4.3.Anesthetics

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country

4.4.Anticonvulsant

4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country

4.5.Antimigraine Drug

4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast, by region
4.5.3.Market analysis, by country

4.6.Antidepressant drugs

4.6.1.Key market trends, growth factors, and opportunities
4.6.2.Market size and forecast, by region
4.6.3.Market analysis, by country

4.7.Opioids

4.7.1.Key market trends, growth factors, and opportunities
4.7.2.Market size and forecast, by region
4.7.3.Market analysis, by country
4.7.4.Tramadol
4.7.5.Hydrocodone
4.7.6.Oxycodone
4.7.7.Others

4.8.Non-narcotic analgesics

4.8.1.Key market trends, growth factors, and opportunities
4.8.2.Market size and forecast, by region
4.8.3.Market analysis, by country

CHAPTER 5:GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY INDICATION

5.1.Overview

5.1.1.Market size and forecast

5.2.Arthritic Pain

5.2.1.Market size and forecast, by region
5.2.1.Market analysis, by country

5.3.Neuropathic pain

5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country

5.4.Cancer Pain

5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country

5.5.Chronic Pain

5.5.1.Market size and forecast, by region
5.5.2.Market analysis, by country

5.6.Post-operative pain

5.6.1.Market size and forecast, by region
5.6.2.Market analysis, by country

5.7.Migraine

5.7.1.Market size and forecast, by region
5.7.2.Market analysis, by country

5.8.Fibromyalgia

5.8.1.Market size and forecast, by region
5.8.2.Market analysis, by country

CHAPTER 6:PAIN MANAGEMENT DRUGS MARKET, BY REGION

6.1.Overview

6.1.1.Market size and forecast

6.2.North America

6.2.1.Key market trends, growth factors, and opportunities
6.2.2.North America Pain Management Drugs Market, by country

6.2.2.1.U.S. Pain Management Drugs Market, by drug class
6.2.2.2.U.S Pain Management Drugs Market, by indications
6.2.2.3.Canada Pain Management Drugs Market, by drug class
6.2.2.4.Canada Pain Management Drugs Market, by indication
6.2.2.5.Mexico Pain Management Drugs Market, by product
6.2.2.6.Mexico Pain Management Drugs Market, by indication

6.2.3.North America Pain Management Drugs Market, by drug class
6.2.4.North America Pain Management Drugs Market, by indication

6.3.Europe

6.3.1.Key market trends, growth factors, and opportunities
6.3.2.Europe Pain Management Drugs Market, by country

6.3.2.1.UK Pain Management Drugs Market, by drug class
6.3.2.2.UK Pain Management Drugs Market, by indication
6.3.2.3.Germany Pain Management Drugs Market, by drug class
6.3.2.4.Germany Pain Management Drugs Market, by indication
6.3.2.5.France Pain Management Drugs Market, by drug class
6.3.2.6.France Pain Management Drugs Market, by indication
6.3.2.7.Italy Pain Management Drugs Market, by drug class
6.3.2.8.Italy Pain Management Drugs Market, by indication
6.3.2.9.Spain Pain Management Drugs Market, by drug class
6.3.2.10.Spain Pain Management Drugs Market, by indication
6.3.2.11.Rest of Europe Pain Management Drugs Market, by drug class
6.3.2.12.Rest of Europe Pain Management Drugs Market, by indication

6.3.3.Europe Pain Management Drugs Market, by drug Class
6.3.4.Europe Pain Management Drugs Market, by indication

6.4.Asia Pacific
6.5.Key market trends, growth factors, and opportunities

6.5.1.Asia-Pacific Pain Management Drugs Market, by country

6.5.1.1.Japan pain management drugs market, by drug class
6.5.1.2.Japan pain management drugs market, by indications
6.5.1.3.China pain management drugs market, by drug class
6.5.1.4.China Pain Management Drugs Market, by indication
6.5.1.5.Australia Pain Management Drugs Market, by drug class
6.5.1.6.Australia Pain Management Drugs Market, by indication
6.5.1.7.India Pain Management Drugs Market, by drug class
6.5.1.8.India Pain Management Drugs Market, by indication
6.5.1.9.South Korea Pain Management Drugs Market, by drug class
6.5.1.10.South Korea Pain Management Drugs Market, by indication
6.5.1.11.Taiwan Pain Management Drugs Market, by drug class
6.5.1.12.Taiwan Pain Management Drugs Market, by indication
6.5.1.13.Rest of Asia-Pacific Pain Management Drugs Market, by drug class
6.5.1.14.Rest of Asia-Pacific Pain Management Drugs Market, by indication

6.5.2.Asia-Pacific Pain Management Drugs Market, by drug Class
6.5.3.Asia-Pacific Pain Management Drugs Market, by indication

6.6.LAMEA

6.6.1.Key market trends, growth factors, and opportunities
6.6.2.LAMEA Pain Management Drugs Market, by country

6.6.2.1.Brazil Pain Management Drugs Market, by drug class
6.6.2.2.Brazil Pain Management Drugs Market, by indication
6.6.2.3.Saudi Arabia Pain Management Drugs Market, by drug class
6.6.2.4.Saudi Arabia Pain Management Drugs Market, by indication
6.6.2.5.South Africa Pain Management Drugs Market, by drug class
6.6.2.6.South Africa Pain Management Drugs Market, by indication
6.6.2.7.Rest of LAMEA Pain Management Drugs Market, by drug class
6.6.2.8.Rest of LAMEA Pain Management Drugs Market, by indication

6.6.3.LAMEA Pain Management Drugs Market, by drug Class
6.6.4.LAMEA Pain Management Drugs Market, by indication

CHAPTER 7:COMPANY PROFILES

7.1.ABBOTT LABORATORIES

7.1.1.Company overview
7.1.2.Company snapshot
7.1.3.Operating business segments
7.1.4.Product portfolio
7.1.5.Business performance

7.2.ELI LILY AND COMPANY

7.2.1.Company overview
7.2.2.Company snapshot
7.2.3.Operating business segments
7.2.4.Product portfolio
7.2.5.Business performance
7.2.6.Key strategic moves and developments

7.3.ENDO HEALTH SOLUTIONS, INC. (ENDO INTERNATIONAL PLC.)

7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Operating business segments
7.3.4.Product portfolio
7.3.5.Business performance.

7.4.GLAXOSMITHKLINE PLC (GSK)

7.4.1.Company overview
7.4.2.Company snapshot
7.4.3.Operating business segments
7.4.4.Product portfolio
7.4.5.Business performance.
7.4.6.Key strategic moves and developments

7.5.JOHNSON & JOHNSON

7.5.1.Company overview
7.5.2.Company snapshot
7.5.3.Operating business segments
7.5.4.Product portfolio
7.5.5.Business performance

7.6.MERCK & CO., INC.

7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segments
7.6.4.Product portfolio
7.6.5.Business performance
7.6.6.Key strategic moves and developments

7.7.MYLAN N.V.

7.7.1.Company overview
7.7.2.Company snapshot
7.7.3.Operating business segments
7.7.4.Product portfolio
7.7.5.Business performance
7.7.6.Key strategic moves and developments

7.8.NOVARTIS INTERNATIONAL AG

7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segments
7.8.4.Product portfolio
7.8.5.Business performance
7.8.6.Key strategic moves and developments

7.9.PFIZER INC.

7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segments
7.9.4.Product portfolio
7.9.5.Business performance
7.9.6.Key strategic moves and developments

7.10.PURDUE PHARMA L.P.

7.10.1.Company overview
7.10.2.Company snapshot
7.10.3.Operating business segments
7.10.4.Product portfolio
7.10.5.Key strategic moves and developments

LIST OF TABLES

TABLE 01.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 02.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY NSAIDS, BY REGION, 2019–2027 ($MILLION)
TABLE 03.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY ANESTHETIC, BY REGION, 2019–2027 ($MILLION)
TABLE 04.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY ANTICONVULSANT, BY REGION, 2019–2027 ($MILLION)
TABLE 05.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY ANTIMIGRAINE DRUG, BY REGION, 2019–2027 ($MILLION)
TABLE 06.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY ANTIDEPRESSANT DRUGS, BY REGION, 2019–2027 ($MILLION)
TABLE 07.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY OPIOIDS, BY REGION, 2019–2027 ($MILLION)
TABLE 08.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY NON-NARCOTIC ANALGESICS, BY REGION, 2019–2027 ($MILLION)
TABLE 09.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 10.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY ARTHMITIC PAIN, BY REGION, 2019–2027 ($MILLION)
TABLE 11.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY NEUROPATHIC PAIN, BY REGION, 2019–2027 ($MILLION)
TABLE 12.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY CANCER PAIN, BY REGION, 2019–2027 ($MILLION)
TABLE 13.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY CHRONIC PAIN, BY REGION, 2019–2027 ($MILLION)
TABLE 14.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY POST-OPERATIVE PAIN, BY REGION, 2019–2027 ($MILLION)
TABLE 15.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY MIGRAINE, BY REGION, 2019–2027 ($MILLION)
TABLE 16.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY FIBROMYALGIA, BY REGION, 2019–2027 ($MILLION)
TABLE 17.GLOBAL PAIN MANAGEMENT DRUGS MARKET REVENUE, BY REGION, 2019–2027 ($MILLION)
TABLE 18.NORTH AMERICA PAIN MANAGEMENT DRUGS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 19.U.S. PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 20.U.S. PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2019–2027 ($MILLION)
TABLE 21.CANADA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 22.CANADA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 23.MEXICO PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 24.MEXICO PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 25.NORTH AMERICA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 26.NORTH AMERICA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 27.EUROPE PAIN MANAGEMENT DRUGS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 28.UK PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 29.UK PAIN MANAGEMENT DRUGS MARKET , BY INDICATION, 2019–2027 ($MILLION)
TABLE 30.GERMANY PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 31.GERMANY PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 32.FRANCE PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 33.FRANCE PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 34.ITALY PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 35.ITALY PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 36.SPAIN PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 37.SPAIN PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 38.REST OF EUROPE PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 39.REST OF EUROPE PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 40.EUROPE PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 41.EUROPE PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 42.ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 43.JAPAN PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 44.JAPAN PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2019–2027 ($MILLION)
TABLE 45.CHINA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 46.CHINA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 47.AUSTRALIA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 48.AUSTRALIA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 49.INDIA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 50.INDIA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 51.SOUTH KOREA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 52.SOUTH KOREA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 53.TAIWAN PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 54.TAIWAN PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 55.REST OF ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 56.REST OF ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 57.ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 58.ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 59.LAMEA PAIN MANAGEMENT DRUGS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 60.BRAZIL PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 61.BRAZIL PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 62.SAUDI ARABIA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 63.SAUDI ARABIA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 64.SOUTH AFRICA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 65.SOUTH AFRICA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 66.REST OF LAMEA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 67.REST OF LAMEA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 68.LAMEA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 69.LAMEA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 70.ABBOTT: COMPANY SNAPSHOT
TABLE 71.ABBOTT: OERATING SEGMENT
TABLE 72.ABBOTT: PRODUCT PORTFOLIO
TABLE 73.ELI LILLY: COMPANY SNAPSHOT
TABLE 74.LILLY: OPERATING SEGMENTS
TABLE 75.ELI LILLY: PRODUCT PORTFOLIO
TABLE 76.ELI LILLY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 77.ENDO: COMPANY SNAPSHOT
TABLE 78.ENDO: OPERATING BUSINESS SEGMENTS
TABLE 79.ENDO: PRODUCT PORTFOLIO
TABLE 80.GSK: COMPANY SNAPSHOT
TABLE 81.GSK: OPERATING SEGMENTS
TABLE 82.GSK: PRODUCT PORTFOLIO
TABLE 83.J&J: COMPANY SNAPSHOT
TABLE 84.J&J: OPERATING BUSINESS SEGMENTS
TABLE 85.J&J: PRODUCT PORTFOLIO
TABLE 86.MERCK & CO., INC.: COMPANY SNAPSHOT
TABLE 87.MERCK & CO., INC.: OPERATING SEGMENTS
TABLE 88.MERCK & CO., INC.: PRODUCT PORTFOLIO
TABLE 89.MERCK & CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 90.MYLAN: COMPANY SNAPSHOT
TABLE 91.MYLAN: OPERATING BUSINESS SEGMENTS
TABLE 92.MYLAN: PRODUCT PORTFOLIO
TABLE 93.NOVARTIS: COMPANY SNAPSHOT
TABLE 94.NOVARTIS: OPERATING SEGMENTS
TABLE 95.NOVARTIS: PRODUCT PORTFOLIO
TABLE 96.PFIZER: COMPANY SNAPSHOT
TABLE 97.PFIZER: OERATING SEGMENT
TABLE 98.PFIZER: PRODUCT PORTFOLIO
TABLE 99.PURDUE: COMPANY SNAPSHOT
TABLE 100.PURDUE: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.GLOBAL PAIN MANAGEMENT DRUGS MARKET SEGMENTATION
FIGURE 02.TOP WINNING STRATEGIES, 2017–2020
FIGURE 03.TOP WINNING STRATEGIES: NATURE AND TYPE, 2017–2020
FIGURE 04.TOP WINNING STRATEGIES: BY YEAR, 2017–2020
FIGURE 05.TOP PLAYER POSTIONING, 2019
FIGURE 06.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
FIGURE 08.MODERATE THREAT OF SUBSTITUTES
FIGURE 09.MODEARTE THREAT OF NEW ENTRANTS
FIGURE 10.MODERATE COMPETITIVE OF RIVALRY
FIGURE 11.DRIVER, RESTRAINSTS AND OPPORTUNITIES
FIGURE 12.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR NSAIDS BY COUNTRY, 2019 & 2027 (%)
FIGURE 13.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR ANESTHETIC BY COUNTRY, 2019 & 2027 (%)
FIGURE 14.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR ANTICONVULSANT BY COUNTRY, 2019 & 2027 (%)
FIGURE 15.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR ANTIMIGRAINE BY COUNTRY, 2019 & 2027 (%)
FIGURE 16.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR ANTIDEPRESSANT DRUGS BY COUNTRY, 2019 & 2027 (%)
FIGURE 17.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR OPIOIDS BY COUNTRY, 2019 & 2027 (%)
FIGURE 18.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR NON-NARCOTIC ANALGESICS BY COUNTRY, 2019 & 2027 (%)
FIGURE 19.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR ARTHMITIC PAIN BY COUNTRY, 2019 & 2027 (%)
FIGURE 20.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR NEUROPATHIC PAIN BY COUNTRY, 2019 & 2027 (%)
FIGURE 21.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR NEUROPATHIC PAIN BY COUNTRY, 2019 & 2027 (%)
FIGURE 22.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR CHRONIC PAIN BY COUNTRY, 2019 & 2027 (%)
FIGURE 23.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR POST-OPERATIVE PAIN BY COUNTRY, 2019 & 2027 (%)
FIGURE 24.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR MIGRAINEBY COUNTRY, 2019 & 2027 (%)
FIGURE 25.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR FIBROMYALGIA BY COUNTRY, 2019 & 2027 (%)
FIGURE 26.ABBOTT: NET SALES, 2017–2019 ($MILLION)
FIGURE 27.ABBOTT: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 28.ABBOTT: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 29.ELI LILLY: NET SALES, 2017–2019 ($MILLION)
FIGURE 30.ELI LILLY: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 31.ENDO: NET SALES, 2017–2019 ($MILLION)
FIGURE 32.ENDO: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 33.GSK: NET SALES, 2017–2019 ($MILLION)
FIGURE 34.GSK: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 35.GSK: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 36.J&J: NET SALES, 2017–2019 ($MILLION)
FIGURE 37.J&J: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 38.J&J: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 39.MERCK & CO., INC.: NET SALES, 2017–2019 ($MILLION)
FIGURE 40.MERCK & CO., INC.: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 41.MERCK & CO., INC.: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 42.MYLAN: NET SALES, 2017–2019 ($MILLION)
FIGURE 43.MYLAN: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 44.NOVARTIS: NET SALES, 2017–2019 ($MILLION)
FIGURE 45.NOVARTIS: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 46.NOVARTIS: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 47.PFIZER: NET SALES, 2017–2019 ($MILLION)
FIGURE 48.PFIZER: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 49.PFIZER: REVENUE SHARE, BY REGION, 2019 (%)

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[疼痛管理薬の世界市場2019–2027:薬剤クラス別(NSAIDS、麻酔薬、抗けいれん薬、抗片頭痛薬、抗うつ薬、オピオイド、非麻薬性鎮痛薬)、疾患別]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆